Phillip Dressel, a 69‑year‑old former landscaper diagnosed with a rare non‑Hodgkin lymphoma, faces a deadline that could determine his financial future. He is among roughly 200,000 plaintiffs accusing Bayer that its Roundup herbicide caused cancer. Bayer reached a $7.5 billion settlement earlier this year, offering participants modest payouts and preserve cash.

Dressel can accept a settlement check estimated at $48,000, or proceed to trial where his lawyers argue a jury could award millions. The choice hinges on risk tolerance; a trial could extend for years and cost thousands, while the settlement provides immediate, albeit limited, relief. His decision deadline falls on June 4 and protect his family’s future.

Bayer’s settlement strategy seeks to cap liability and restore investor confidence after the Roundup litigation eroded its market value. Analysts watch how individual cases like Dressel’s influence the overall payout pool; a surge in trials could pressure the company to increase future compensation or face additional regulatory scrutiny. The outcome will shape the herbicide’s financial legacy for shareholders worldwide.